CymaBay Therapeutics Inc (NASDAQ:CBAY) shares fell 8% during mid-day trading on Monday . The company traded as low as $1.59 and last traded at $1.62, 3,274,659 shares traded hands during trading. An increase of 206% from the average session volume of 1,069,866 shares. The stock had previously closed at $1.76.
CBAY has been the topic of a number of recent analyst reports. Leerink Swann lowered CymaBay Therapeutics to a “hold” rating and set a $2.50 price objective on the stock. in a research report on Tuesday, November 26th. Oppenheimer lowered CymaBay Therapeutics from an “outperform” rating to a “hold” rating in a research report on Monday, November 25th. SunTrust Banks lowered CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 25th. BidaskClub upgraded CymaBay Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 23rd. Finally, Zacks Investment Research lowered CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and three have assigned a buy rating to the company’s stock. CymaBay Therapeutics currently has a consensus rating of “Hold” and an average price target of $6.85.
The stock has a market cap of $113.36 million, a P/E ratio of -1.31 and a beta of 1.07. The company has a quick ratio of 13.12, a current ratio of 13.12 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $4.43 and a two-hundred day moving average price of $6.40.
In other news, CEO Sujal Shah bought 5,000 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were bought at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the transaction, the chief executive officer now owns 111,900 shares of the company’s stock, valued at $618,807. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased 11,900 shares of company stock worth $59,600 over the last quarter. 4.20% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of the stock. Millennium Management LLC lifted its position in shares of CymaBay Therapeutics by 401.5% in the third quarter. Millennium Management LLC now owns 3,723,797 shares of the biopharmaceutical company’s stock worth $19,065,000 after buying an additional 2,981,292 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of CymaBay Therapeutics in the third quarter worth about $1,765,000. Voloridge Investment Management LLC purchased a new stake in shares of CymaBay Therapeutics in the third quarter worth about $330,000. Barclays PLC lifted its position in shares of CymaBay Therapeutics by 100.2% in the third quarter. Barclays PLC now owns 802,752 shares of the biopharmaceutical company’s stock worth $4,111,000 after buying an additional 401,778 shares in the last quarter. Finally, Tower Research Capital LLC TRC purchased a new stake in shares of CymaBay Therapeutics in the third quarter worth about $61,000. Institutional investors own 93.36% of the company’s stock.
About CymaBay Therapeutics (NASDAQ:CBAY)
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.